Healthcare Industry News: Alzheimer's disease
News Release - April 9, 2007
Neuroptix Corp. Opens New Corporate Headquarters in Acton
Pioneer in non-invasive early detection of Alzheimer's through laser eye scanning opens new offices in Boston suburbsACTON, Mass.--(HSMN NewsFeed)--Neuroptix Corporation, a Massachusetts-based pioneer in the early detection of Alzheimer's disease, today announced that it has opened its corporate headquarters in Acton, Mass., as it ramps up development of its innovative technology for non-invasive diagnosis of Alzheimer's disease through laser eye scanning.
Paul Hartung, President and CEO of Neuroptix, said, "We are very pleased to announce expanded operations in our new facility, following our successful Series A funding and new hires of senior personnel, as we work to further develop our diagnostic platform for Alzheimer's disease toward commercialization."
The new facility, leased to Neuroptix by Wedgewood Realty, is located at 20 Main Street in Acton, Mass.
About Neuroptix Corporation
Neuroptix is creating and developing an innovative, non-invasive eye test for the early diagnosis of Alzheimer's disease. Neuroptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive and widely available test, enabling early diagnosis and treatment. The company collaborates with major pharmaceutical companies who use Neuroptix technology in development of new Alzheimer's drugs, and with academic institutions to promote research in this area.
For more information, please visit our website at www.neuroptix.com, email us at info@neuroptix.com, or call us at (978) 263-0005.
Source: Neuroptix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
